Seshu Tyagarajan Sells 7,000 Shares of Candel Therapeutics (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the sale, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This represents a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Monday, June 29th, Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00.

Candel Therapeutics Price Performance

CADL opened at $12.35 on Friday. The company has a market capitalization of $945.02 million, a price-to-earnings ratio of -8.76 and a beta of -0.51. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38. The firm has a 50-day moving average price of $10.01 and a 200-day moving average price of $7.60. Candel Therapeutics, Inc. has a twelve month low of $4.35 and a twelve month high of $13.82.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). Equities analysts expect that Candel Therapeutics, Inc. will post -1.3 EPS for the current year.

Hedge Funds Weigh In On Candel Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CADL. Cookson Peirce & Co. Inc. purchased a new stake in Candel Therapeutics during the 2nd quarter valued at about $618,000. Wellington Management Group LLP purchased a new position in Candel Therapeutics in the second quarter worth about $2,119,000. Bank of America Corp DE purchased a new position in Candel Therapeutics in the second quarter worth about $2,873,000. Legal & General Group Plc bought a new position in shares of Candel Therapeutics in the second quarter worth approximately $63,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Candel Therapeutics in the second quarter worth approximately $175,000. 13.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus started coverage on Candel Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $22.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Candel Therapeutics in a research report on Thursday, August 13th. Wall Street Zen lowered shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, UBS Group reissued a “buy” rating on shares of Candel Therapeutics in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.29.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.